Dr Andy Richards, Chairman
A biotechnology entrepreneur and business angel. Founder of Chiroscience and Business Development Director until merger in 1999 with Celltech. He is currently a Non-executive Director of Vectura, Biowisdom, Babraham Bioscience Technology Ltd, Daniolabs, Cancer Research Technology Ltd and Theradeas Ltd. He is a founder member of the “Cambridge Angels” a group of high net worth private investors and a member of the Council of UEA
Dr Fran Crawford, CEO
20 years experience in strategic growth and management of emerging biotech companies. Previously she has been COO of a technology management company managing IP portfolios and mentoring start-up companies, and R & D Director of Sirus Pharmaceuticals Ltd, a clinical stage biotechnology company which was sold to Arakis in 2003. She has extensive practical experience of product development (formulation to market) in Europe and US
Mr David Alcraft, Director
35 years in international roles in Pharmaceutical Industry. Founder of Bridgehead International a consultancy company offering technical and commercial evaluation, pricing and reimbursement strategies and business development and licensing services. He has a track record of product development and commercialisation.
Mr Dean Slagel, Non Executive Director
17 years of biotechnology and pharmaceutical business management experience across 4 countries. Starting in global business development at Tillotts Pharma in Switzerland, he spent 8 years with Ferring in the UK, France and Denmark, moving from regional operations to global business development and became Global Business Development Director in 2000. During this period, he completed his MBA and was responsible for two significant international licensing deals. He established and has managed Esperante's initial fund since late 2003, during which time he has been responsible for 8 portfolio company investments in the USA, UK, France and Germany to date.
Mr Stéphane Mery, Non Executive Director
Stephane manages the investments for Beringea's ProVen Health VCT. Prior to joining Beringea Stephane was Associate Director of Healthcare Investment at Noble from May 2007 and Fund Manager of the Bloomsbury Bioseed Fund from November 2000.